Best Life Sciences Platforms and Tools Companies in Ontario, Canada
The 112 best Life Sciences Platforms and Tools companies in Ontario, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: iVexSol.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Ontario
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | iVexSol Developer of a platform for the production of vectors | $39M | 40 mo ago | 34 | Rodney Rietze Co-Founder & CEO | — | — | — | — |
| 2 | Nicoya Life Provider of hyperspectral optical microscopes for surface analysis | $35M | 54 mo ago | 105 | — | WordPressUnbounceElementor+36 | Top 5M | — | 2 launchs |
| 3 | Intellipharmaceutics International Specialty company developing generic controlled oral solid dosage drugs | $24M | 79 mo ago | 11 | Isa Odidi Chief Executive Officer | — | — | — | — |
| 4 | Therapure Biopharma Contract development and manufacturing organization that specializes in the development, manufacture of… | $24M | 129 mo ago | 225 | — | — | — | 52 patents Hemoglobin-targeted drug carriers and large‑scale protein/albumin purification technologies | — |
| 5 | Covalon Develops technologies, products and services to address the needs of medical device companies and healthcare… | $20M | 80 mo ago | 88 | Val DiTizio Co-Founder | WordPressApple iCloud MailMicrosoft 365+32 | Top 10M | — | 3 launchs |
| 6 | Mirexus Biotechnologies Safe & Natural polysaccharide based Nanomaterials | $17M | 102 mo ago | — | Phil Whiting President & CEO | — | — | — | — |
| 7 | High Q Technologies Developer of quantum-enabled electron paramagnetic resonance systems for protein analysis | $10M | 27 mo ago | 24 | Wendy Hinchey CEO | — | — | — | 1 job opening · 1 partnership |
| 8 | CryoStasis Developer of subzero unfrozen cell preservation platform for cell and gene therapy | $8M | 34 mo ago | 8 | — | — | — | 10 patents Cryogenic preservation and storage systems for biological specimens and tissues | — |
| 9 | Axela Platforms for multiplex nucleic acid and protein analysis | $8M | 104 mo ago | 20 | M Cynthia Goh Founder | — | — | — | — |
| 10 | Insception Largest cord blood program in Canada | $7M | 164 mo ago | 57 | — | WordPressMySQLPHP+28 | Top 10M | — | — |
| 11 | Microbix Developer of various biological products and technological solutions | $7M | 39 mo ago | 100 | — | Cart FunctionalityWooCommerceWordPress+33 | Top 10M | — | — |
| 12 | DoseBiome Provider of prebiotic and probiotic products | $4M | — | 9 | Ted Jin Founder & CEO | — | — | — | — |
| 13 | Acorn Provider of stem cell biobanking services | $3M | 28 mo ago | 19 | Patrick Pumputis Co-Founder & CSO | WordPressMySQLPHP+35 | Top 10M | — | — |
| 14 | Aereus Technologies Copper alloy based coating for bacterial protection | $3M | 69 mo ago | 12 | — | — | — | — | — |
| 15 | Nanovista Developing multimodal visualization agents | $2M | 100 mo ago | 3 | Jinzi Zheng Co-Founder | — | — | — | — |
| 16 | Actlabs Provider of analytical testing and development services for various industries. | $2M | 254 mo ago | 452 | Eric Hoffman Founder | WordPressPleskMySQL+28 | Top 5M | — | 1 job opening |
| 17 | Mesosil Developer of antimicrobial materials | $2M | 24 mo ago | 5 | — | — | — | 6 patents Controlled ion and metal‑oxide release systems for dental and medical therapeutics | — |
| 18 | Ranomics Database of rare genetic variants | $1M | 117 mo ago | 6 | — | WixSentryBootstrap+17 | Top 50M | 7 patents High-throughput multisite saturation mutagenesis and splice‑junction variant analysis for gene engineering | — |
| 19 | CTT Pharmaceuticals Oral thin-film wafers for drug delivery | $1M | 97 mo ago | — | — | — | — | — | — |
| 20 | Crescita Therapeutics Developer of over-the-counter and prescription products for the treatment and care of skin diseases | $1M | 105 mo ago | 78 | Serge Verreaul CEO | WixSentryBootstrap+17 | Top 10M | 38 patents Topical solid-forming and rinse-off pharmaceutical delivery formulations for skin applications. | — |
| 21 | D5Pharma Developer of aptamer-based therapeutics to treat cancer and inflammatory diseases | $1M | 206 mo ago | — | Leigh Revers CEO | — | — | 5 patents Therapeutic DNA aptamers targeting CD200R1 immune checkpoint modulation | — |
| 22 | Micromensio Developer of on-chip sensors for point-of-need diagnostics solution | $780K | 57 mo ago | 2 | Enver Kilinc Co-Founder & CTO | — | — | — | — |
| 23 | Affinity Biologicals Range of products for thrombosis, hemostasis, and medical diagnostics | $500K | 180 mo ago | 25 | — | WordPressMySQLPHP+13 | Top 10M | — | — |
| 24 | Neurescence Provider of miniature microscope for imaging multiple regions of the brain | $350K | 61 mo ago | 10 | — | — | — | 15 patents Compact medical optical imaging and lens‑fiber focusing connectors for diagnostic devices | — |
| 25 | Spartan Bioscience DNA testing systems | $284K | 135 mo ago | 54 | — | — | — | 57 patents Rapid nucleic acid sample preparation, amplification, and detection technologies for diagnostics | — |
| 26 | Membio Developer of single-use bioreactors for cell and gene therapies | $280K | 79 mo ago | 11 | Shane Kilpatrick Founder & CEO | — | — | 11 patents Advanced zoned cell culture bioreactors for controlled bioprocessing | — |
| 27 | Spindle Biotech Providers of tools for gene editing research | $250K | 84 mo ago | 2 | Aaron Chung CEO | — | — | 6 patents In vitro RNA synthesis reagents and methods for producing synthetic RNA molecules | — |
| 28 | Amino Provider of lab equipment for bacterial transformations and culture growth | $250K | 128 mo ago | 6 | — | Cart FunctionalityShopifySentry+32 | Top 5M | — | — |
| 29 | Avro Lifesciences Developer of dermal therapies and patches for pediatric use | $150K | 100 mo ago | 19 | — | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Ontario
#1
Seed · Waterloo, Ontario · founded 2013 · 24 employees$10.2Mraised▾
Developer of quantum-enabled electron paramagnetic resonance systems for protein analysis. The company’s systems resolve complex problems in protein dynamics for drug discovery. It offers a sample measurement service to provide researchers with insights into molecular dynamics. The organization’s technology aims to redefine standards in protein structure determination.
- Feb 2024Seed$3.8M
- 2019Seed$6.5M
#2
Seed · Toronto, Ontario · founded 2016 · 5 employees$1.6Mraised▾
Mesosil develops antimicrobial materials to prevent infection at the medical device-tissue interface. It acts as local antibacterial filler material. It utilizes antibacterial self-assembled materials. The product has applications for dental restoratives and dental implant surfaces.
- Jun 2024Seed$1.6M
- 2016Seed—
#3
Series A · Toronto, Ontario · founded 2017 · 19 employees$3.3Mraised▾
Provider of stem cell biobanking services. The services include young cell preservation, non-invasive approaches, etc. This has applications in gene therapy, stem cell therapeutics, tissue engineering, organ regeneration, etc.
- Jan 2024Series A—
- Apr 2019Seed—
- Jan 2019Seed$3.3M
- 2017Seed$30K
#4
Series A · Toronto, Ontario · founded 2018 · 34 employees$39Mraised▾
iVexSol is a manufacturer and developer of the vector. It offers its flagship intelligent transformative platform for developing lentiviral vector cell lines.
- Jan 2023Series A$23.8M
- Dec 2020Series A$13M
- Aug 2020Seed$250K
- Sep 2019Seed$2M
#5
Public · Mississauga, Ontario · founded 1988 · 100 employees$7Mraised▾
Developer of various biological products and technological solutions. The company has expertise in virology and protein biochemistry. The Company developed a pipeline of selected biological technologies including VIRUSMAX (Influenza Virus Yield Enhancement Technology), LumiSort (Semen Sexing Technology), and the thrombolytic drug, Kinlytic (Urokinase). The company's core focus is in Infectious Disease Antigen, including cell culture, molecular biology, and others.
- Mar 2023Grant (prize money)$840K
- May 2021Post IPO$1.1M
- Jan 2020Post IPO$1.8M
- Jun 2018Post IPO$75K
#6
Seed · Ottawa, Ontario · founded 2022 · 8 employees$8Mraised▾
Developer of subzero unfrozen cell preservation platform for cell and gene therapy. The company’s platform uses media, temperature, and pressure to preserve biological material. The media formulation leverages cold shock inhibitors and membrane protectants. Temperature systems include devices and shipping solutions. Pressure systems lower the freezing point and cell metabolism, enabling long-term storage.
- Jul 2023Seed$8M
#7
Series A · Kitchener, Ontario · founded 2012 · 105 employees$35Mraised▾
Provider of hyperspectral optical microscopes for surface analysis. It offers a personalized device for the measurement and characterization of biomolecular interactions. Its surface plasmon resonance sensor enables interactions between proteins, antibodies, DNA, RNA, peptides, polymers, and more to be studied with nanoscale resolution.
- Dec 2021Series A$15.5M
- Jun 2020Grant (prize money)$221K
- Jan 2020Series A$10M
- May 2019Conventional Debt—
#8
Deadpooled · Toronto, Ontario · founded 1998 · 11 employees$24.4Mraised▾
Intellipharmaceutics International develops controlled-release drug therapies by leveraging its hypermatrix technology, a proprietary multidimensional controlled-release drug delivery platform. The company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, CVS, GIT, diabetes and pain. The Hhpermatrix family of technologies includes intelliFoam, IntelliGITransporter, intelliMatrix, intelliOsmotics, intelliPaste, intelliPellets, intelliShuttle and point of divergence drug delivery system (nPODDDS). The company's products include focalin XR, effexor XR, protonix, glucophage XR, seroquel XR, lamictal XR, keppra XR, pristiq, oleptro, coreg CR, oxyContin and lyrica
- Nov 2019Post IPO$250K
- Mar 2018Post IPO$3.3M
- Mar 2018Post IPO$1.8M
- Oct 2017Post IPO$4M
#9
Public · Toronto, Ontario · founded 2003 · 88 employees$20Mraised▾
Covalon Technologies develops technologies, products and services to address the needs of medical device companies and healthcare providers. They work with medical device manufacturers to offer their partners the experience, breadth and depth of knowledge using their patent portfolio and in-house lab facilities.
- Sep 2019Post IPO$5.5M
- Aug 2018Conventional Debt$13.7M
- Aug 2016Post IPO—
- Aug 2013Post IPO$750K
#10
Funding Raised · Mississauga, Ontario · founded 2008 · 225 employees$24.2Mraised▾
Therapure Biopharma focuses on manufacturing complex biologics and on developing, manufacturing, and selling its blood and plasma-related therapeutic products. It operates through three divisions: Therapure Biomanufacturing (Mammalian cell line based CDMO), Therapure Biologics (Plasma-derived products), and Therapure Innovations (Proprietary drug development). It provides contract development and manufacturing services for integrated biologics and also offers drug discovery, research, and development services. The company also focuses on the development of a portfolio of its own plasma-derived protein therapeutics through its technology, PlasmaCap EBA (for efficient capture of plasma proteins at high yields and purities). Therapure Innovations' lead candidates TBI 302 (liver cancer) and TBI 304H (anemia) are undergoing phase I trials while TBI 301 (Hep C) is in the discovery stage. The company is funded by the Catalyst Capital Group since its inception. The company's CDMO business and certain rights to their plasma products and technology for the Chinese market were acquired by a JV between 3SBio and CPE funds.
- Aug 2015Conventional Debt$20M
- Apr 2010Grant (prize money)$4.2M
#11
Series A · Guelph, Ontario · founded 2008$16.9Mraised▾
Safe & Natural polysaccharide based Nanomaterials
#12
Early Stage · Burlington, Ontario · founded 2009 · 12 employees$2.6Mraised▾
Aereus Technologies is a biotech company commercializing Aereus Shield, a thin, non-tarnishing copper alloy coating which can be applied to solid surface to kill harmful bacteria on contact. In Canada, Aereus Shield is marketed as an antimicrobial for use exclusively on Class I and Class II medical devices. The coating provides a cost-effective intervention against common hospital pathogens and other harmful bacteria present in publicly exposed surfaces. The company signed a licensing agreement with Techlem Medical under which Aereus Shield coated healthcare equipments will be sold to hospitals by Techlem.
- Aug 2020Unattributed$2.6M
- Feb 2017PE—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Ontario is moving
A read on the academic research around Bioinformatics in Ontario — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 59 papers.
Ontario Institute for Cancer Research and allied institutions dominantly pursue cancer genomics and bioinformatics network research with cautious optimism (stance 0.45), recent output tripling amid mixed breakthrough and concern findings.
- Ontario Institute for Cancer Research29
- Children\'s Hospital of Eastern Ontario9
- Public Health Ontario9
- Ontario Brain Institute5
- Ontario Genomics4
- Genome1→3
- Cancer1→3
- Computational biology2
- Disease2
- Identification (biology)2
- Cancer2
- Comparability2
- Genome2
- Transcriptome2
- Phenotype2
- Polygenic risk score1
- MAMMOGRAPHIC DENSITY1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.